Press Releases

Keyword Search
 
PDS Biotechnology | Former Edge Therapeutics
February 21, 2019 - Edge Therapeutics Announces Full Year 2018 Financial Results
Read More
November 26, 2018 - Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
Read More
November 1, 2018 - Edge Therapeutics Reports Third Quarter 2018 Financial Results
Read More
August 1, 2018 - Edge Therapeutics Reports Second Quarter 2018 Financial Results
Read More
June 27, 2018 - Edge Therapeutics Announces Updated Results from Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
May 1, 2018 - Edge Therapeutics Reports First Quarter 2018 Financial Results
Read More
April 30, 2018 - Edge Therapeutics Announces Review of Strategic Alternatives
Read More
March 28, 2018 - Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
March 1, 2018 - Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Read More
February 26, 2018 - Edge Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 1, 2018
Read More
February 8, 2018 - Edge Therapeutics to Present at Upcoming Investor Conferences in February
Read More
December 29, 2017 - Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis
Read More
November 6, 2017 - Edge Therapeutics to Present at the 26th Annual Credit Suisse Healthcare Conference
Read More
November 1, 2017 - Edge Therapeutics Reports Third Quarter 2017 Financial Results
Read More
October 18, 2017 - Edge Therapeutics Announces Third Quarter Financial Results Conference Call on November 1, 2017
Read More
October 6, 2017 - Edge Therapeutics to Present at the Neurocritical Care Society 15th Annual Meeting
Read More
September 20, 2017 - Edge Therapeutics to Present at Upcoming Investor Conferences
Read More
September 19, 2017 - Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors
Read More
August 1, 2017 - Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress
Read More
July 18, 2017 - Edge Therapeutics Announces Second Quarter Financial Results Conference Call on August 1, 2017
Read More
July 6, 2017 - Edge Therapeutics Announces Commercial Supply Agreement for EG-1962 with Oakwood Laboratories
Read More
June 15, 2017 - Edge Therapeutics to Participate in the JMP Securities Life Science Conference
Read More
June 8, 2017 - Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency
Read More
June 2, 2017 - Edge Therapeutics to Present at Jefferies 2017 Global Healthcare Conference
Read More
May 10, 2017 - Edge Therapeutics to Present at Bank of America Merrill Lynch 2017 Health Care Conference
Read More
May 3, 2017 - Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress
Read More
April 21, 2017 - Edge Therapeutics Announces Conference Call on May 3, 2017 to Discuss First Quarter 2017 Financial Results
Read More
April 19, 2017 - Edge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock
Read More
March 29, 2017 - Edge Therapeutics to Present at Needham & Company’s 16th Annual Healthcare Conference
Read More
March 13, 2017 - Edge Therapeutics Announces First Patient Randomized in Study of Intracisternal Administration of EG-1962 in Adults with Aneurysmal Subarachnoid Hemorrhage
Read More
March 3, 2017 - Edge Therapeutics to Present at Cowen and Company 37th Annual Healthcare Conference on March 8, 2017
Read More
March 2, 2017 - Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Read More
February 23, 2017 - Edge Therapeutics Announces Conference Call on March 2, 2017 to Discuss Fourth Quarter and Full Year 2016 Financial Results
Read More
February 21, 2017 - Edge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)
Read More
February 17, 2017 - Edge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017
Read More
February 8, 2017 - Edge Therapeutics to Present at Investor Conferences in February
Read More
December 9, 2016 - Edge Therapeutics Announces Publication of Phase 1/2 Data on EG-1962 for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Peer-Reviewed Medical Journal, Stroke
Read More
November 2, 2016 - Edge Therapeutics to Present at Investor Conferences in November
Read More
November 1, 2016 - Edge Therapeutics Reports Third Quarter Financial Results
Read More
October 25, 2016 - Edge Therapeutics to Host Conference Call on November 1, 2016 to Discuss Third Quarter Financial Results
Read More
October 17, 2016 - Edge Therapeutics Appoints Chief Operating Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)
Read More
September 8, 2016 - Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor Conferences in September
Read More
September 6, 2016 - Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting the Potential Clinical and Health Economic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
September 1, 2016 - Edge Therapeutics to Present Additional Data from Phase 1/2 NEWTON Study of EG-1962 at Two Scientific Conferences in September
Read More
August 3, 2016 - Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights
Read More
August 2, 2016 - Edge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc.
Read More
July 29, 2016 - Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage
Read More
July 27, 2016 - Edge Therapeutics to Host Conference Call on August 3, 2016 to Discuss Second Quarter Financial Results
Read More
July 6, 2016 - Edge Therapeutics Announces Appointment of Harry J. Sacks, M.D., FAAP, as Vice President, Clinical Development
Read More
June 24, 2016 - Edge Therapeutics Granted U.S. Patent Covering the Expanded Use of Lead Candidate EG-1962
Read More
June 10, 2016 - Edge Therapeutics’ Chief Accounting and Operations Officer Bert Marchio Receives the New Jersey Tech Council Deal of the Year Award
Read More
June 2, 2016 - Edge Therapeutics to Present at Upcoming Investor Conferences
Read More
May 13, 2016 - Edge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage
Read More
May 6, 2016 - Edge Therapeutics Chief Financial Officer Andrew J. Einhorn Receives CFO Studio 2016 CFO Success Award
Read More
May 3, 2016 - Edge Therapeutics Reports First Quarter 2016 Financial Results
Read More
April 26, 2016 - Edge Therapeutics to Host a Conference Call on May 3, 2016 to Discuss First Quarter 2016 Financial Results
Read More
April 5, 2016 - Edge Therapeutics to Present at the 15th Annual Needham Healthcare Conference
Read More
March 8, 2016 - Edge Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results
Read More
March 2, 2016 - Edge Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference
Read More
March 1, 2016 - Edge Therapeutics to Host a Conference Call on March 8, 2016 to Discuss Fourth Quarter and Full-Year 2015 Financial Results
Read More
February 19, 2016 - Edge Therapeutics Announces New Data Highlighting the Potential Pharmacoeconomic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
February 10, 2016 - New Data From the Phase 1/2 NEWTON Study of Edge Therapeutics’ EG-1962 to be Presented at the International Stroke Conference 2016
Read More
February 3, 2016 - Edge Therapeutics to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
Read More
January 10, 2016 - Edge Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
Read More
December 8, 2015 - Edge Therapeutics to Participate in Guggenheim Securities 3rd Annual Healthcare Conference
Read More
November 20, 2015 - Edge Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Read More
November 6, 2015 - Edge Therapeutics Reports Third Quarter 2015 Financial Results
Read More
November 5, 2015 - Edge Therapeutics Names W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary
Read More
November 4, 2015 - Edge Therapeutics to Present at the 24th Annual Credit Suisse Healthcare Conference
Read More
October 12, 2015 - Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients With Subarachnoid Hemorrhage
Read More
October 6, 2015 - Edge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
Read More
September 30, 2015 - Edge Therapeutics Announces Pricing of Its Initial Public Offering
Read More
August 19, 2015 - Edge Therapeutics Reports Positive Top-Line Phase 1/2 NEWTON Trial Results of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
May 28, 2015 - Edge Therapeutics Completes Enrollment in Phase 1/2 NEWTON Study of EG-1962 for Patients with Ruptured Brain Aneurysm
Read More
April 9, 2015 - Edge Therapeutics Raises $72.5 Million Through Successive Series C-1 and C-2 Financings
Read More
February 11, 2015 - Edge Therapeutics Reports Initial Data from its Phase 1/2 NEWTON Trial for EG-1962 for Improvement of Outcomes after Ruptured Brain Aneurysm
Read More
January 8, 2015 - Edge Therapeutics Announces Appointment of Renu Vaish, M.S. As Vice President, Regulatory Affairs
Read More
November 18, 2014 - Edge Therapeutics Announces Multi-Year Research Collaboration with Leading Academic Medical Center
Read More
September 30, 2014 - Edge Therapeutics, Evonik Granted EG-1962 Composition Of Matter Patent
Read More
September 8, 2014 - Edge Therapeutics Obtains $10 Million Venture Loan Facility with Hercules Technology Growth Capital
Read More
June 5, 2014 - Edge Therapeutics Initiates Enrollment of Second Cohort in Phase 1/2 NEWTON Study of EG-1962 for Improvement of Outcome After Ruptured Brain Aneurysm
Read More
April 8, 2014 - Edge Therapeutics Expands Senior Management Team and Opens New Headquarters to Support Continued Growth
Read More
October 30, 2013 - Edge Therapeutics Enrolls First Patient in Phase 1/2 NEWTON Study of EG-1962 for Prevention of Delayed Cerebral Ischemia
Read More
September 10, 2013 - Edge Therapeutics Elects Robert J. Spiegel, MD To Board of Directors – Former Schering-Plough Chief Medical Officer Joins Board
Read More
June 10, 2013 - FDA Accepts IND Application For Edge Therapeutics’ EG-1962 (nimodipine microparticles) – Single Dose EG-1962 To Be Compared To Current Standard Of Care
Read More
June 4, 2013 - Edge Therapeutics Raises $18 Million to Advance Clinical Development of Potentially Life-Saving Hospital Products
Read More
January 22, 2013 - Edge Therapeutics Appoints Dr. Sol Barer and Isaac Blech as Chairman and Vice Chairman of Its Board of Directors
Read More
December 11, 2012 - December 11, 2012 - Bert Marchio, Edge CFO, featured in CFO Studio Magazine
Read More
October 1, 2012 - Edge CEO Brian Leunther featured in CEO CFO Magazine
Read More
August 22, 2012 - Edge Therapeutics Appoints Drug-Delivery Luminary Dr. Robert Langer To Chair Scientific Advisory Committee
Read More
June 28, 2012 - Edge and Three Other Companies Meet With Lt. Governor Kim Guadagno
Read More
June 8, 2012 - Government of Canada Awards CA$700,000 Toward Phase 2 Study of Edge Therapeutics’ Lead Compound to Improve Outcomes After Brain Injury
Read More
April 3, 2012 - MPI Research and Edge Therapeutics Partner to Advance Development of Life-Saving Therapies After Brain Hemorrhage
Read More
March 16, 2012 - Edge Featured in NJ Business Incubation Network Newsletter
Read More
December 2, 2011 - Edge Therapeutics Receives Success Award From New Jersey Small Business Development Centers
Read More
November 17, 2011 - Edge Therapeutics Appoints James J. Loughlin to Board of Directors
Read More
September 7, 2011 - Edge Presenting at Rodman & Renshaw
Read More
September 7, 2011 - Edge appoints Dr. Sol J. Barer to Board
Read More
April 8, 2011 - Edge Featured in Start-Up Magazine
Read More
March 15, 2011 - Edge Therapeutics featured in BioCentury
Read More
February 11, 2011 - NimoGel™ Shows Promise at Preventing Delayed Complications of Sudden Brain Injury in a Preclinical Study Presented at the International Stroke Conference
Read More
December 10, 2010 - Edge Therapeutics Featured in Drug Discovery News
Read More
November 22, 2010 - Edge Therapeutics Featured in Drug Delivery Technology
Read More
November 3, 2010 - SurModics and Edge Therapeutics Collaborate on Development of Sustained-Release Neurological Product
Read More
November 2, 2010 - Edge Therapeutics Awarded $244,479 Qualifying Therapeutic Development Project Grant
Read More
October 27, 2010 - Edge Therapeutics Named Incubator Company to Watch by New Jersey Technology Council
Read More
July 20, 2010 - Edge Therapeutics and SurModics Collaborate to Develop a Drug Delivery Technology for Treatment of Secondary Brain Injury After Stroke or Traumatic Brain Injury (TBI)
Read More
July 8, 2010 - The New Jersey Economic Development Authority Awards Funding to Edge Therapeutics for Treatments to Prevent Secondary Brain Damage after Sudden Brain Injury
Read More
June 17, 2010 - Edge Therapeutics Appoints Scientific Advisory Board Members and Business Advisors
Read More

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts